MEDIGEN BIOTECHNOLOGY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.7 TWD | -0.64% |
|
+1.84% | -13.62% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,248 | 8,612 | 8,228 | 7,999 | 4,685 | 6,243 |
| Enterprise Value (EV) 1 | 6,460 | 9,373 | 7,149 | 5,993 | 2,385 | 4,520 |
| P/E ratio | -14.1 x | -33.7 x | -24.3 x | -152 x | -6.92 x | -11.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 15.3 x | 15.6 x | 13.4 x | 2.04 x | 4.44 x | 5.39 x |
| EV / Revenue | 15.9 x | 17 x | 11.6 x | 1.53 x | 2.26 x | 3.9 x |
| EV / EBITDA | -11.7 x | -16.5 x | -10 x | 6.2 x | -1.59 x | -4.19 x |
| EV / FCF | -16.5 x | -55.5 x | -8.72 x | -24.3 x | -3.31 x | -23.8 x |
| FCF Yield | -6.05% | -1.8% | -11.5% | -4.11% | -30.2% | -4.21% |
| Price to Book | 4.06 x | 6.34 x | 4.53 x | 3.34 x | 2.14 x | 3.92 x |
| Nbr of stocks (in thousands) | 138,686 | 138,686 | 138,986 | 139,363 | 139,446 | 139,346 |
| Reference price 2 | 45.05 | 62.10 | 59.20 | 57.40 | 33.60 | 44.80 |
| Announcement Date | 4/1/19 | 3/31/20 | 4/1/21 | 3/30/22 | 3/31/23 | 3/15/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 407.3 | 552.3 | 615.5 | 3,922 | 1,056 | 1,158 |
| EBITDA 1 | -554.4 | -567.3 | -711.4 | 967.4 | -1,498 | -1,078 |
| EBIT 1 | -762.4 | -762.3 | -912.2 | 780 | -1,667 | -1,233 |
| Operating Margin | -187.19% | -138.02% | -148.19% | 19.89% | -157.87% | -106.51% |
| Earnings before Tax (EBT) 1 | -784.5 | -817.8 | -880 | 1,136 | -1,873 | -1,279 |
| Net income 1 | -442.7 | -255.7 | -337.9 | -52.61 | -675.9 | -561.3 |
| Net margin | -108.68% | -46.3% | -54.9% | -1.34% | -64.01% | -48.48% |
| EPS 2 | -3.192 | -1.844 | -2.431 | -0.3786 | -4.858 | -4.028 |
| Free Cash Flow 1 | -390.6 | -168.9 | -820.2 | -246.5 | -720.7 | -190.2 |
| FCF margin | -95.9% | -30.58% | -133.25% | -6.29% | -68.25% | -16.43% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/1/19 | 3/31/20 | 4/1/21 | 3/30/22 | 3/31/23 | 3/15/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 212 | 761 | - | - | - | - |
| Net Cash position 1 | - | - | 1,079 | 2,006 | 2,300 | 1,723 |
| Leverage (Debt/EBITDA) | -0.3832 x | -1.341 x | - | - | - | - |
| Free Cash Flow 1 | -391 | -169 | -820 | -247 | -721 | -190 |
| ROE (net income / shareholders' equity) | -26.2% | -29.4% | -23.6% | 19.6% | -30% | -25.6% |
| ROA (Net income/ Total Assets) | -10.1% | -10.1% | -10.4% | 6.79% | -11.5% | -8.33% |
| Assets 1 | 4,398 | 2,530 | 3,254 | -774.5 | 5,897 | 6,740 |
| Book Value Per Share 2 | 11.10 | 9.790 | 13.10 | 17.20 | 15.70 | 11.40 |
| Cash Flow per Share 2 | 4.100 | 5.850 | 15.90 | 15.40 | 14.60 | 16.00 |
| Capex 1 | 120 | 110 | 133 | 143 | 148 | 38.4 |
| Capex / Sales | 29.34% | 19.99% | 21.55% | 3.64% | 14.03% | 3.32% |
| Announcement Date | 4/1/19 | 3/31/20 | 4/1/21 | 3/30/22 | 3/31/23 | 3/15/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -13.62% | 165M | |
| +0.17% | 42.19B | |
| +10.92% | 42.24B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.23% | 24.63B | |
| -24.79% | 18.2B | |
| +26.69% | 12.01B | |
| -3.13% | 11.76B | |
| +6.57% | 10.4B |
- Stock Market
- Equities
- 3176 Stock
- Financials Medigen Biotechnology Corp.
